Vivakor, Inc. 8-K

What Happened

• Vivakor, Inc. filed an 8-K on December 29, 2025 reporting that Nasdaq has determined its common stock no longer meets listing standards and that trading was suspended. Nasdaq initially notified the company on March 18, 2025 that its closing bid price had been below the $1.00 minimum (Rule 5550(a)(2)) and gave a 180‑day cure period (to Sept 15, 2025), later extended 180 days to March 16, 2026.
• On December 19, 2025 Nasdaq advised that Vivakor’s stock had a closing bid of $0.10 or less for ten consecutive trading days, invoking the Low Priced Stocks Rule (Listing Rule 5810(c)(3)(A)(iii)) and rendering the company ineligible for the remainder of the Second Grace Period. Nasdaq also cited a separate deficiency — failure to obtain required shareholder approval under Listing Rule 5635(d) — as an additional basis for delisting. Trading was suspended at the opening on December 26, 2025 and a Form 25‑NSE will be filed to remove the securities from Nasdaq listing and registration.
• Vivakor appealed Nasdaq’s delisting notice on December 24, 2025; a hearing before the Nasdaq Hearings Panel is scheduled for January 29, 2026. The company said it will present a plan to regain compliance but noted there is no assurance the appeal or plan will succeed.

Key Details

• Initial Nasdaq notice: March 18, 2025 — minimum $1.00 bid price deficiency (Rule 5550(a)(2)); cure period to Sept 15, 2025.
• Extension: Additional 180‑day Second Grace Period granted to March 16, 2026.
• December 19, 2025 letter: closing bid $0.10 or less for 10 consecutive trading days → ineligible for remaining Second Grace Period; cited Listing Rule 5810(c)(3)(A)(iii).
• Trading suspended: December 26, 2025; appeal filed Dec 24, 2025; hearing set for January 29, 2026. Nasdaq also cited failure to comply with Listing Rule 5635(d) (shareholder approval) as a separate delisting basis.

Why It Matters

• For shareholders, suspension and likely delisting mean reduced liquidity and less accessible trading (Nasdaq quotation removed via Form 25‑NSE), which can make buying or selling shares harder and may depress marketability and price.
• The company is pursuing an appeal and preparing a plan to regain compliance, but the 8‑K makes clear there is no assurance of a successful outcome. Investors should monitor the January 29, 2026 hearing and any follow-up disclosures about the appeal outcome or alternate trading arrangements (e.g., OTC markets).